Ginkgo Bioworks Holdings Net Income 2020-2022 | DNA

Ginkgo Bioworks Holdings net income from 2020 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Ginkgo Bioworks Holdings Annual Net Income
(Millions of US $)
2021 $-1,830
2020 $-127
2019 $-119
Ginkgo Bioworks Holdings Quarterly Net Income
(Millions of US $)
2022-03-31 $-591
2021-12-31 $-1,548
2021-09-30 $-102
2021-06-30 $-107
2021-03-31 $-74
2020-12-31
2020-09-30 $-26
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.228B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00